InjectionCritical Care Injection Infusion

BARICITINIB

Baricitinib · Janus kinase (JAK) inhibitor

InjectionCritical Care Injection Infusion

BARICITINIBProspero Healthcare

Baricitinib is classed as a janus kinase (JAK) inhibitor and is supplied as tablets. Its standard indications include rheumatoid arthritis, and it is offered for pharmaceutical supply and export.

Uses

Rheumatoid arthritis

Enquire about this product

Specifications are indicative; availability, composition, pack sizes and registration requirements may vary by destination market.

01Specification

Product details

Composition: Baricitinib
Available strengthsIndicative: 2 mg · 4 mg
Dosage form: Injection
Therapeutic category: Critical Care Injection Infusion
Therapeutic class: Janus kinase (JAK) inhibitor
Packing: Vial or ampoule, single unit or tray pack
Storage: Store below 25 °C, protected from light. Do not freeze.

02Related

From the same category

View the category

Injection
METHYLPREDNISOLONE ACETATE
METHYLPREDNISOLONE ACETATEInjection
Injection
Pantoprazole Injection
Pantoprazole InjectionInjection
Injection
Thiocolchicoside Injection
Thiocolchicoside InjectionInjection
Injection
ANAESTHETIC & NEUROMUSCULAR
ANAESTHETIC & NEUROMUSCULARInjection
Injection
Dacarbazine Injection
Dacarbazine InjectionInjection
Injection
Gemcitabine Injection
Gemcitabine InjectionInjection